olmesartan profile

olmesartan: an active metabolite of CS 866 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Pathways (4)

olmesartan is involved in 4 pathway(s), involving a total of 1722 unique proteins and 1563 unique compounds

ID Source	ID
PubMed CID	158781
CHEMBL ID	1516
CHEBI ID	48416
SCHEMBL ID	94037
MeSH ID	M0403284

Synonym
HY-17004
HMS3393K12
olmesartan (usan/inn)
144689-24-7
D05246
MLS001424016
MLS000759446
smr000466337
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
olmesartan
DB00275
4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-
olmesartan [usan]
votum
rnh-6270
4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
CHEBI:48416 ,
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylic acid
HMS2051K12
4-(hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1h-tetrazol-5-yl)-1,1''-biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
bdbm50241364
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2''-(1h-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylic acid
CHEMBL1516 ,
nsc-759810
olmesartan medoxomil impurity, olmesartan-
rnh 6270
4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1h-imidazole-5-carboxylic acid
omesartan
cs-088 ,
L001097
cs 088
4-(2-hydroxypropan-2-yl)-2-propyl-1-({4-[2-(1h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1h-imidazole-5-carboxylic acid
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
NCGC00246968-01
nsc759810
pharmakon1600-01505206
de-092
olmesartan medoximil
8w1iqp3u10 ,
hsdb 8214
olmesartan [usan:inn:ban]
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1h-imidazole-5-carboxylate
ec 646-413-5
unii-8w1iqp3u10
nsc 759810
HMS2235O24
CCG-100868
FT-0631169
NCGC00246968-02
olmesartan medoxomil impurity, olmesartan- [usp impurity]
olmesartan [vandf]
olmesartan medoxomil impurity a [ep impurity]
olmesartan [who-dd]
olmesartan [mi]
olmesartan [inn]
CS-0576
AKOS015900241
olmesartan acid
S5581
HMS3369I09
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
VTRAEEWXHOVJFV-UHFFFAOYSA-N
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazole-5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl) -2-propyl-1-{4-[2-(tetrazole -5-yl)phenyl]phenyl}methylimidazole-5-carboxylic acid
OLM ,
SCHEMBL94037
NC00118
MLS006011945
smr004703526
W-201270
4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic acid
diclofenacdiethylamine
1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylic acid
AKOS024458255
HMS3604J06
mfcd00914967
DTXSID2040571 ,
C21543
AC-9385
olmesartan, >=98% (hplc)
olmesartan medoxomil imp. a (ep); 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]-1h-imidazole-5-carboxylic acid; olmesartan; olmesartan acid; olmesartan medoxomil impurity a
4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]-1h-imidazole-5-carboxylic acid (olmesartan)
1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylic acid
benicar;olmetec
Q421156
1-((2'-(2H-TETRAZOL-5-YL)-[1,1'-BIPHENYL]-4-YL)METHYL)-4-(2-HYDROXYPROPAN-2-YL)-2-PROPYL-1H-IMIDAZOLE-5-CARBOXYLIC ACID
AS-10242
O0507
BCP12007
EN300-122328
4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylic acid
CCG-269198
NCGC00246968-04
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid.
O-125
olmesartan 100 microg/ml in acetonitrile:methanol
1h-imidazole-5-carboxylicacid,4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
A853148
Z1541758605
4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1h-imidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1h-imidazole-5-carboxylic acid
dtxcid0020571

Excerpt	Reference
"Olmesartan, which is an angiotensin II receptor blocker, reportedly causes spruelike enteropathy, with intestinal villous atrophy as its typical histopathological finding. "	( Ehira, N; Kaneko, S; Kishi, K; Kobayashi, H; Matsuda, K; Mizuta, Y; Nakamura, A; Shiratori, S; Uebayashi, M; Yagisawa, M, 2021)
"Olmesartan is an inhibitor of the angiotensin II receptor developed for the treatment of hypertension, and recent studies show that it exerts anti-inflammatory effects in arthritis."	( Chen, Q; Liu, J; Liu, Y; Ma, Y; Shang, Y; Yang, X; Zhang, Y, 2022)
"Olmesartan is a novel angiotensin receptor blocker with promising antihypertensive properties and has recently been reported to exert anti-inflammatory and antioxidative stress effects."	( Wang, J; Yang, S; Zheng, B; Zhou, D, 2021)
"Olmesartan is an angiotensin II receptor blocker, approved in 2002 by the Food and Drug Administration for the treatment of hypertension. "	( Barbara, G; Bellacosa, L; Capuani, F; Cogliandro, RF; Cremon, C; Marasco, G; Mauloni, PA; Paone, C; Stanghellini, V; Vasuri, F, 2021)
"Olmesartan medoxomil is an antihypertensive drug of the class of angiotensin II type 1 (AT1) receptor antagonists (or blockers), characterized by tight and prolonged binding to AT1 receptor compared to other molecules within the same class. "	( Battistoni, A; Coluccia, R; Mastromarino, V; Santolamazza, C; Tocci, G; Volpe, M, 2017)
"Olmesartan is an angiotensin II type 1 receptor blocker commonly used in the treatment of hypertension. "	( Aguiar Losada, B; Elejalde Guerra, JI; González Recio, P; Leturia Frade, I; Modesto Dos Santos, JL; Terry López, OA, 2017)
"Olmesartan is an angiotensin II receptor blocker, used to treat arterial hypertension. "	( Héron, F; Le Besnerais, M; Marie, I; Sadki, A, 2019)
"Olmesartan is a long-lasting ARB which proved to achieve a comparable or more effective action in lowering BP when compared to other ARBs."	( Omboni, S; Volpe, M, 2018)
"Olmesartan is an angiotensin II receptor antagonist, used in the treatment of hypertension. "	( Shenbagaraj, L; Swift, G, 2018)
"Olmesartan is an effective and safe antihypertensive agent, but special attention should be paid to high-risk patients, such as those with coronary disease, to avoid an excessive reduction in blood pressure."	( Barrios, V; Escobar, C, 2013)
"Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics."	( Daikuhara, H; Fukunaga, K; Ohshima, T, 2014)
"Olmesartan is a type of angiotensin II receptor inhibitor that can reduce the incidence of cardiovascular events. "	( Fu, YM; Gong, X; Shao, L; Zou, Y, 2015)
"The olmesartan is a selective antagonist of angiotensin II indicated for the treatment of essential hypertension. "	( Colardelle, P; Ould Sidi Mohamed, M, 2016)
"Olmesartan is an antihypertensive medication belonging to the angiotensin II receptor blocker class of drugs that has recently been associated with severe enteropathy. "	( Choi, EY; McKenna, BJ, 2015)
"Olmesartan is a therapy used for the management of hypertension available since 2002. "	( Campos Ruiz, A; Marra-López Valenciano, C; Urtasun Arlegui, L, 2016)
"The olmesartan is a selective antagonist of angiotensin II indicated for the treatment of essential hypertension. "	( Colardelle, P; Ould Sidi Mohamed, M, 2016)
"Olmesartan medoxomil is an orally given angiotensin II receptor antagonist indicated for the treatment of hypertension."	( Kodati, D; Kotakonda, HK; Yellu, N, 2017)
"Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in diastolic blood pressure or systolic blood pressure to achieve goal blood pressure."	( Ruilope, LM, 2008)
"Olmesartan is a potential ARB inducing activation of angiotensin-converting enzyme 2 (ACE2) that hydrolyzes Ang II to Ang 1-7, and has shown a beneficial effect on ventricular remodeling."	( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2010)
"Olmesartan medoxomil is an angiotensin II (Ang II) receptor blocker (ARB) that has been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. "	( Chrysant, SG; Dimas, B; Shiraz, M, 2007)
"Olmesartan is a selective angiotensin II type 1 receptor (AT1) antagonist. "	( Ichihara, K; Kaneta, S; Kano, S; Satoh, K, 2008)

Excerpt	Reference
"Olmesartan has a reverse-remodeling effect on AF-induced structural changes, indicating that it may be useful for preventing AF recurrence after the termination of sustained AF."	( Kumagai, K; Nakashima, H, 2007)
"Olmesartan (OLM) has potent anti-oxidant and anti-inflammatory characters, yet having limited bioavailability."	( Darwish, SF; El-Dakroury, WA; Radwan, E; Sallam, AM, 2021)
"Olmesartan has significant blood pressure lowering effect via modulating renin-angiotensin system although its mechanism of action in DNR-induced renal injury is largely unknown."	( Arozal, W; Arumugam, S; Gounder, VK; Harima, M; Nomoto, M; Pitchaimani, V; Suzuki, K; Thandavarayan, RA; Watanabe, K, 2014)
"Olmesartan has been linked with increased risk of cardiovascular mortality and sprue-like enteropathy. "	( Etminan, M; Eurich, DT; Lin, M; Padwal, R, 2014)
"Olmesartan use has been associated with chronic diarrhoea and weight loss due to severe sprue-like enteropathy, yet this is still not well known among clinicians. "	( Gonzalo, DH; Martelli, MG; Naik, DK; Pannu, D; Sharma, AK, 2015)
"Olmesartan has been also widely examined in combination of either hydrochlorothiazide or amlodipine, as well as with both drugs in a single-pill triple combination, showing improvements in antihypertensive efficacy without significant effects on tolerability."	( de la Sierra, A; Volpe, M, 2013)
"Olmesartan has a reverse-remodeling effect on AF-induced structural changes, indicating that it may be useful for preventing AF recurrence after the termination of sustained AF."	( Kumagai, K; Nakashima, H, 2007)

Excerpt	Reference
"Olmesartan can increase circulating endothelial progenitor cells number and the serum levels of eNOS and NO."	( Fu, YM; Gong, X; Shao, L; Zou, Y, 2015)
"Olmesartan may suppress atherosclerosis via reducing not only superoxide production but also the overload of oxidative stress in this animal model."	( Fujita, M; Kishimoto, C; Kita, T; Murayama, T; Shimada, K; Yokode, M, 2011)
"Olmesartan abolished the increase in p21 expression, whereas neither eplerenone nor hydralazine affected it."	( Deguchi, K; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Minamino, T; Mori, H; Nakano, D; Nishiyama, A, 2012)

Excerpt	Reference
"40 olmesartan-treated patients (14.3%) and 53 placebo-treated patients (18.7%) developed secondary cardiovascular outcomes (HR: 0.65, P = 0.042)."	( Chan, JC; Haneda, M; Harada, A; Imai, E; Ito, S; Kobayashi, F; Makino, H; Yamasaki, T, 2013)
"Olmesartan treatment was found to generate beneficial effects on MetS parameters in HT patients but did not produce any significant increases in serum PPAR-γ transcription factor concentration."	( Akbal, E; Akyürek, N; Akyürek, Ö; Güneş, F, 2014)
"Olmesartan treatment (3 mg/kg per day) for 4 weeks significantly lowered systolic blood pressure but did not affect body weight during the study period in KKAy mice."	( Azushima, K; Kanaoka, T; Kobayashi, R; Maeda, A; Matsuda, M; Ohki, K; Ohsawa, M; Tamura, K; Tokita, Y; Tsurumi-Ikeya, Y; Umemura, S; Uneda, K; Wakui, H; Yamashita, A, 2014)
"Olmesartan treatment significantly ameliorated blood-brain barrier (BBB) disruption induced by CKD in 5XFAD mice."	( Hasegawa, Y; Kim-Mitsuyama, S; Nakagawa, T; Uekawa, K, 2017)
"Olmesartan treatment substantially elevated both the baseline SI and SG levels of the ZF rats."	( Feng, Q; Guo, J; Lao, GC; Liu, W; Ran, JM; Xie, B; Xu, G; Zhang, Y, 2008)
"Olmesartan treatment significantly lowered the blood pressure of PAH mice, and hypertrophy as well as increased plasma levels of cardiac injury markers were also markedly reduced."	( Fukamizu, A; Honjo, K; Inaba, S; Ishida, J; Nakamura, S; Sakairi, A; Sugiyama, F; Yagami, K, 2008)
"In olmesartan-treated patients, CBF significantly increased in the affected and unaffected hemispheres, and CRC increased significantly in the affected hemisphere."	( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2009)
"Olmesartan treatment significantly decreased SBP to 130.4+/-4.2mm Hg (P < .001) and DBP to 78.2+/-7.0mm Hg (P < .001)."	( Ikeda, K; Kawabe, K; Nagata, R, 2010)
"Olmesartan treatment resulted in a significant decrease in CAVI, serum A-FABP levels, and hsCRP, besides a significant reduction of blood pressure."	( Doi, M; Hirohata, S; Izumi, R; Kamikawa, S; Kusachi, S; Miyoshi, T; Ninomiya, Y; Ogawa, H; Sakane, K; Usui, S, 2011)
"Olmesartan treatment effectively suppressed the myocardial protein expressions of inflammatory markers in comparison to the vehicle-treated rats."	( Gurusamy, N; Kodama, M; Lakshmanan, AP; Ma, M; Nagata, M; Sukumaran, V; Suzuki, K; Takagi, R; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2012)
"Olmesartan treatment led to a decrease of cystatin C level."	( Ahbap, E; Basturk, T; Borlu, F; Damar, AB; Koc, Y; Mazi, E; Sakaci, T; Unsal, A, 2011)
"The olmesartan treatment induced a 16.2 ± 7.7% decrement of the mean R2* in CKD patients, suggesting that this drug had an intrarenal hypoxia ameliorating effect."	( Chetsurakarn, S; Eiam-Ong, S; Limkuansuwan, P; Manotham, K; Ongvilawan, B; Tanamai, J; Tungsanga, K; Urusopone, P, 2012)
"Olmesartan-treated mice also showed significant attenuation of left ventricular dilatation and dysfunction, as well as significantly greater infarct wall thickness, although the absolute size of the infarct scar was unchanged."	( Aoyama, T; Esaki, M; Fujiwara, H; Kanamori, H; Kawasaki, M; Li, Y; Maruyama, R; Minatoguchi, S; Miyata, S; Nakagawa, M; Ogino, A; Okada, H; Takemura, G; Ushikoshi, H, 2007)
"Olmesartan treatment significantly ameliorated glomerulosclerosis and dramatically decreased urinary Smad1 (from 3.9 +/- 2.9 to 0.3 +/- 0.3 ng/mg creatinine, P < 0.05)."	( Abe, H; Arai, H; Araki, M; Doi, T; Fukatsu, A; Iehara, N; Kanamori, H; Kita, T; Matsubara, T; Matsuura, M; Mima, A; Nagai, K; Takahashi, T; Tamura, Y; Tominaga, T; Torikoshi, K, 2008)
"Olmesartan treatment reversed virtually all neuroendocrine and histopathological cardiac changes induced by EAM, thus providing a mechanistic insight into this phenomenon."	( de Bold, AJ; Georgalis, T; Kuroski de Bold, ML; Ogawa, T; Veinot, JP, 2008)
"Olmesartan treatment caused a 61% reduction in the cross-sectional area of the neointima, from 0.27+/-0.01 mm2 in vehicle-treated rats to 0.11+/-0.01 mm2 in olmesartan-treated rats."	( Ferrario, CM; Igase, M; Kohara, K; Miki, T; Nagai, T, 2008)
"Treatment with olmesartan/azelnidipine for 2 years resulted in greater improvements in CBP, LVMI, and LV diastolic function, and arterial stiffness compared with olmesartan/amlodipine. "	( Saito, Y; Takami, T, 2013)
"Treatment with olmesartan and nifedipine significantly improved BP."	( Dimitriadis, F; Kinoshita, Y; Martin, DT; Ohmasa, F; Oikawa, R; Oiwa, H; Saito, M; Satoh, I; Shimizu, S; Tomita, S; Tsounapi, P, 2014)
"Treatment with olmesartan significantly decreased systolic blood pressure and ventricular hypertrophy, attenuated fibrosis, and improved diastolic function (all P < 0.05)."	( Cui, X; Fu, M; Ge, J; Hu, K; Liao, J; Sun, A; Xu, J; Zhou, J; Zhu, H; Zou, Y, 2014)
"Treatment with olmesartan reversed tacrolimus-induced changes in the biochemical markers (BUN and creatinine) of nephrotoxicity."	( Al-Harbi, MM; Al-Harbi, NO; Alabidy, AD; Almukhallafi, AF; Imam, F; Iqbal, M; Nadeem, A; Sayed-Ahmed, MM, 2014)
"Treatment with olmesartan or valsartan significantly ameliorated these changes in aged SHR."	( Hasegawa, Y; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Ma, M; Maeda, M; Nakagawa, T; Ogawa, H; Sueta, D; Toyama, K; Uekawa, K; Waki, H, 2014)
"Treatment with olmesartan for 8 weeks does not improve fatty acid oxidation or the activity of enzymes associated with oxidative metabolism in skeletal muscle from overweight and obese individuals. "	( Anderson, AS; Boutagy, NE; Davy, BM; Davy, KP; Frisard, MI; Hulver, MW; Marinik, EL; McMillan, RP; Rivero, JM, 2015)
"Posttreatment with olmesartan significantly reduced escape latency (P < 0.01) on water maze test, retention trial latency (P < 0.05) on passive avoidance test, and retention time of outer zone (P < 0.01) on open-field test in 5XFAD subjected to BCCAO."	( Hasegawa, Y; Kim-Mitsuyama, S; Matsui, K; Nakagata, N; Nakagawa, T; Senju, S; Uekawa, K, 2017)
"The treatment with olmesartan normalized insulin signaling, including expression of glucose transporter-4, whereas the treatment with enalapril was ineffective for the insulin receptor and less effective than olmesartan on the insulin-receptor substrate-1, phosphorylated-mammalian target of rapamycin and glucose transporter-4."	( Agabiti-Rosei, E; Assanelli, D; Boari, GE; De Ciuceis, C; Favero, G; Flati, V; Martinotti, S; Paiardi, S; Pasini, E; Platto, C; Porteri, E; Rezzani, R; Rizzoni, D; Rodella, LF; Speca, S; Toniato, E, 2008)
"Treatment with olmesartan, nifedipine, or both drugs had no effect on systolic blood pressure, and each treatment achieved similar suppression of 4-HNE expression."	( Hayashi, T; Kitada, K; Kitaura, Y; Matsumoto, C; Matsumura, Y; Miyamura, M; Mori, T; Okada, Y; Sohmiya, K; Ukimura, A; Yamashita, C; Yoshioka, T, 2010)
"Treatment with olmesartan reduced urinary protein-to-creatinine ratio independent of blood glucose and increased average renal vessel lumen diameter in the perfused kidneys of STZ-induced DM rats, predominantly in preglomerular vessels, and then improved renal excretory capability. "	( Chen, JF; Li, HW; Song, HF; Sun, NL, 2011)
"Treatment with olmesartan attenuated the myocardial mRNA expressions of proinflammatory cytokines, [Interleukin (IL)-1β, monocyte chemoattractant protein-1, tumor necrosis factor-α and interferon-γ)] and the protein expression of tumor necrosis factor-α compared with that of vehicle-treated rats."	( Gurusamy, N; Kodama, M; Lakshmanan, AP; Ma, M; Sukumaran, V; Suzuki, K; Thandavarayan, RA; Veeraveedu, PT; Watanabe, K; Yamaguchi, K, 2011)
"Treatment with olmesartan delayed the onset of microalbuminuria independent of the baseline BP and the degree of BP reduction."	( Chatzykirkou, C; Haller, H; Ito, S; Izzo, JL; Januszewicz, A; Katayama, S; Menne, J; Mimran, A; Rabelink, TJ; Ritz, E; Ruilope, LM; Rump, LC; Viberti, G, 2012)
"Treatment with olmesartan (3 mg/kg per day) significantly inhibited oxidative stress and atherosclerosis, whereas its inhibitory effects were more marked in female than in male or ovariectomized mice."	( Horiuchi, M; Ide, A; Iwai, M; Li, HS; Li, JM; Min, LJ; Mogi, M; Okumura, M; Suzuki, H; Suzuki, J; Tsuda, M, 2005)
"Treatment with olmesartan (n=9) significantly increased EPCs from 231+/-24 to 465+/-71 per high-power field (P<0.05), but not hematopoietic progenitor cells."	( Bahlmann, FH; de Groot, K; Fliser, D; Haller, H; Hertel, B; Mueller, O, 2005)
"Treatment with olmesartan (10 or 100 mg/kg/day) had no effect on blood pressure but attenuated proteinuria in a dose-dependent manner."	( Abe, Y; Baba, R; Fan, YY; Fujita, M; Hosomi, N; Kimura, S; Kohno, M; Miyatake, A; Nagai, Y; Nishiyama, A; Sun, GP, 2006)
"Treatment with olmesartan or pravastatin reduced the development of atherosclerosis as compared to the control group (-46 and -39%, respectively)."	( Havekes, LM; Jukema, JW; Kleemann, R; Kooistra, T; Princen, HM; van der Hoorn, JW, 2007)
"Treatment with olmesartan significantly decreased serum glucose and cholesterol levels in HSCD mice, with a slight decrease in blood pressure."	( Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K, 2007)
"Treatment with olmesartan blocked leukocyte recruitment by antagonizing mononuclear cells-associated oxidative stress."	( Hagita, S; Osaka, M; Shimokado, K; Yoshida, M, 2008)

Role	Description
antihypertensive agent	Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
angiotensin receptor antagonist	A hormone antagonist that blocks angiotensin receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
biphenylyltetrazole	A member of the class of biphenyls that consists of a biphenyl ring system substituted by a tetrazole ring at an unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Metabolism	1496	1108
Biological oxidations	150	276
Phase I - Functionalization of compounds	69	175
Olmesartan Action Pathway	7	4

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	44.6684	0.0447	17.8581	100.0000	AID485294
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	25.1189	0.0355	20.9770	89.1251	AID504332
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0000	2.8005	10.0000	AID1210069
Cytochrome P450 2J2	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0120	2.5312	9.4700	AID1210069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Platelet glycoprotein VI	Homo sapiens (human)	Kd	300.0000	0.0411	0.0411	0.0411	AID1692279
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	Km	71.8000	0.0391	2.9388	6.4000	AID680212
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	Km	42.6000	0.0076	3.2018	10.0000	AID680560
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
fatty acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
icosanoid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
regulation of heart contraction	Cytochrome P450 2J2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
organic acid metabolic process	Cytochrome P450 2J2	Homo sapiens (human)
positive regulation of platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet activation	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
collagen-activated signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
platelet aggregation	Platelet glycoprotein VI	Homo sapiens (human)
immune response-regulating signaling pathway	Platelet glycoprotein VI	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
iron ion binding	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
linoleic acid epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activity	Cytochrome P450 2J2	Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activity	Cytochrome P450 2J2	Homo sapiens (human)
heme binding	Cytochrome P450 2J2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2J2	Homo sapiens (human)
transmembrane signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein binding	Platelet glycoprotein VI	Homo sapiens (human)
collagen binding	Platelet glycoprotein VI	Homo sapiens (human)
signaling receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
collagen receptor activity	Platelet glycoprotein VI	Homo sapiens (human)
protein tyrosine kinase binding	Platelet glycoprotein VI	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2J2	Homo sapiens (human)
extracellular exosome	Cytochrome P450 2J2	Homo sapiens (human)
cytoplasm	Cytochrome P450 2J2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2J2	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
membrane raft	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
cell surface	Platelet glycoprotein VI	Homo sapiens (human)
extracellular exosome	Platelet glycoprotein VI	Homo sapiens (human)
tetraspanin-enriched microdomain	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Platelet glycoprotein VI	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID680560	TP_TRANSPORTER: transport in OATP1B1-expressing oocytes	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID568788	Binding affinity to angiotensin AT1 receptor in bovine adrenal cortex membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1217705	Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1211555	In vitro apparent biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1211548	In vivo apparent biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1217711	Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217712	Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1216814	Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay	2011	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID183748	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 6 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID183742	Inhibitory activity against AII-Induced Pressor response at 0.3 mg/Kg at 1 hr	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID183745	Inhibitory activity against AII-Induced Pressor response at 0.3 mg/Kg at 6 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1211549	Unbound fraction in Sprague-Dawley rat plasma at 100 uM by equilibrium dialysis method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1217729	Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID568885	Antagonist activity at angiotensin AT1 receptor in guinea pig aorta assessed as reduction of angiotensin 2-induced contractile response	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1211554	Biliary excretion index in sandwich cultured Sprague-Dawley rat hepatocytes after 15 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1737435	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as intrinsic activity measured after 39 hrs by dual luciferase reporter assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1217704	Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID680780	TP_TRANSPORTER: transport in hCMV cells	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID1217707	Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID182953	In vivo inhibitory activity against angiotensin II induced pressor response in anesthetized normotensive rats	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1217728	Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1737443	Cytotoxicity against human HS5 cells assessed as cell death at 10 uM measured after 72 hrs by Propidium iodide stain based FACS analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID183743	Inhibitory activity against AII-Induced Pressor response at 0.3 mg/Kg at 3 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID680781	TP_TRANSPORTER: transport in MRP2-expressing vesicles	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID1217727	Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID588962	Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1B1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID679052	TP_TRANSPORTER: biliary excretion in EHBR rat	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID1211551	Drug uptake in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID588963	Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1B3	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID679564	TP_TRANSPORTER: transport in NTCP-transfected HEK-293 cells	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID183746	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 1 hr	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1217708	Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID39641	In vitro for inhibition of [125I]-angiotensin II (0.1 nM) binding to angiotensin II receptor type 1 in membrane fractions of bovine adrenal cortex	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID1282228	Displacement of 125I-[Sar1, Ile8] AngII from rat AT1 receptor expressed in COS1 cells	2016	Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3	Tactical Approaches to Interconverting GPCR Agonists and Antagonists.
AID1211552	In vitro intrinsic biliary clearance in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID680212	TP_TRANSPORTER: transport in OATP1B3-expressing oocytes	2006	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 34, Issue:5	OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.
AID183747	Inhibitory activity against AII-Induced Pressor response at 1 mg/Kg at 3 hour	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.
AID568884	Displacement of radiolabeled angiotensin 2 from angiotensin AT1 receptor in bovine adrenal cortex membranes	2010	Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24	Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.
AID1737437	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 20 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1692279	Binding affinity to recombinant GP6 (unknown origin) at protein to compound ratio of 1 : 1 to 1 : 10 by 2D 15N-1H TROSY-HSQC NMR spectroscopy	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID588977	Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP2	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1217709	Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1211553	Drug uptake in iv dosed Sprague-Dawley rat liver after 5 hrs by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1210069	Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method	2013	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1	Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1737434	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as maximal activation at 10 uM measured after 39 hrs by dual luciferase reporter assay relative to pioglitazo	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1217710	Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1217706	Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1737436	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 10 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1211550	In vivo intrinsic biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (0.12)	18.2507
2000's	187 (23.29)	29.6817
2010's	532 (66.25)	24.3611
2020's	83 (10.34)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	185 (22.00%)	5.53%
Reviews	64 (7.61%)	6.00%
Case Studies	99 (11.77%)	4.05%
Observational	23 (2.73%)	0.25%
Other	470 (55.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (133)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis[NCT00382213]	Phase 3	210 participants	Interventional	2000-06-30	Completed
Prospective, Multicentric, Large Scale Observational Study to Evaluate the Effectiveness & Safety of Xirtam H in Indian Patients Suffering From Hypertension.[NCT01219556]		8,704 participants (Actual)	Observational	2010-11-30	Completed
Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke[NCT01198496]	Phase 4	5,000 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension-[NCT01101009]	Phase 4	486 participants (Actual)	Interventional	2010-04-30	Completed
Single Dose Crossover Comparative Bioavailability Study of Olmesartan Medoxomil 40 mg Film-coated Tablets in Healthy Adult Subjects Under Fasting Conditions.[NCT03951051]	Phase 1	32 participants (Actual)	Interventional	2019-05-06	Completed
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension[NCT02407210]	Phase 3	304 participants (Anticipated)	Interventional	2015-01-31	Recruiting
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication[NCT05103332]	Phase 2	672 participants (Actual)	Interventional	2021-11-05	Active, not recruiting
Olmesartan Versus Nebivolol in Management of Hypertension in Acute Ischemic Stroke[NCT03655964]	Phase 2	60 participants (Actual)	Interventional	2018-08-20	Completed
Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA)[NCT02360956]	Phase 4	100 participants (Anticipated)	Interventional	2014-12-31	Recruiting
An Open-label, Randomized, 2X2 Crossover Study to Compare the Pharmacokinetics and Safety Between DWJ1351 and Co-administration of Amlodipine/Olmesartan and Rosuvastatin in Healthy Male Subjects[NCT03753477]	Phase 1	64 participants (Actual)	Interventional	2017-12-22	Completed
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia[NCT03009487]	Phase 3	265 participants (Actual)	Interventional	2017-01-31	Completed
A Multi-center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab. for Patients With Hypertension and Dyslipidemia[NCT05184179]		7,000 participants (Anticipated)	Observational	2019-12-01	Enrolling by invitation
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect. Comparison Between an ATII Receptor Antagonist and a Diuretic.[NCT03560804]		60 participants (Actual)	Interventional	2014-11-10	Completed
A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension[NCT00403481]	Phase 4	192 participants (Actual)	Interventional	2006-11-30	Completed
ACCESS STUDY (Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study) ARB/CCB Combination Therapy: Efficacy vs an ACE-inhibitor/CCB Combination and Use as First Line Therapy.[NCT01089452]	Phase 4	0 participants (Actual)	Interventional		Withdrawn(stopped due to Study not started due to administrative reasons.)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension[NCT00846365]	Phase 3	1,085 participants (Actual)	Interventional	2009-03-31	Completed
A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension[NCT02495324]	Phase 4	369 participants (Actual)	Interventional	2015-06-30	Completed
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fed Condition.[NCT03319706]	Phase 1	34 participants (Actual)	Interventional	2010-08-31	Completed
Phase 4 Study on Olmesartan, an Angiotensin Receptor Blocker, on Ambulatory Blood Pressure Change, Vitamin D Levels and Urinary Sodium Excretion of Patients With Hypertension[NCT00854763]		100 participants (Anticipated)	Observational	2009-04-30	Not yet recruiting
Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy[NCT00430508]	Phase 3	972 participants (Actual)	Interventional	2007-02-28	Completed
Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension[NCT00751829]	Phase 3	417 participants (Actual)	Interventional	2003-07-31	Completed
Add-on Study of CCBs or Diuretics in Essential Hypertension Not Achieving Target Blood Pressure on Olmesartan Medoxomil Alone[NCT00858702]	Phase 4	105 participants (Actual)	Interventional	2005-02-28	Completed
Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy[NCT00430950]	Phase 3	1,011 participants (Actual)	Interventional	2007-02-28	Completed
A Prospective, Open Label, Single Arm Study to Evaluation the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Elderly Patients With Hypertension[NCT00412932]	Phase 4	178 participants (Actual)	Interventional	2006-12-31	Completed
Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study[NCT01132768]	Phase 4	114 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Low recruitment)
A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertens[NCT00796159]		1,723 participants (Actual)	Observational	2007-07-31	Completed
A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure[NCT01180205]	Phase 4	576 participants (Anticipated)	Interventional	2010-08-31	Active, not recruiting
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension[NCT00696241]	Phase 3	1,275 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension[NCT00996281]	Phase 3	837 participants (Actual)	Interventional	2009-10-31	Completed
Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome[NCT00676845]	Phase 3	133 participants (Actual)	Interventional	2008-08-31	Completed
A Prospective, Open-label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil and Amlodipine Based Treatment Regimen in Hypertensive, Type 2 Diabetic Subjects[NCT00654745]	Phase 4	207 participants (Actual)	Interventional	2008-05-31	Completed
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study[NCT05660135]		4,000 participants (Anticipated)	Observational	2022-06-20	Recruiting
A Non-interventional, Multi Center, Prospective Observational Study to Evaluate the Effect of Improving Systolic Blood Pressure and Low-density Lipoprotein Cholesterol Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar[NCT05411887]		3,000 participants (Anticipated)	Observational	2022-06-20	Recruiting
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease[NCT04394117]	Phase 4	787 participants (Actual)	Interventional	2020-06-19	Completed
An Open Label, Randomized, 2-Sequence, Multiple-Dose, Cross-Over Study to Investigate the Drug-Drug Interaction of Sevikar and Crestor in Healthy Adult Volunteers[NCT02089399]	Phase 1	32 participants (Actual)	Interventional	2014-05-31	Completed
Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension.[NCT00751751]	Phase 3	441 participants (Actual)	Interventional	2003-06-30	Completed
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Efficacy, Safety, and Tolerability of TAK-536 in Patients With Mild to Moderate Uncomplicated Essential Hypertension[NCT00759551]	Phase 2	555 participants (Actual)	Interventional	2004-08-31	Completed
Vascular Improvement With Olmesartan Medoxomil Study[NCT00772499]	Phase 4	100 participants (Actual)	Interventional	2002-11-30	Completed
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia[NCT02735707]	Phase 3	10,000 participants (Anticipated)	Interventional	2016-04-11	Recruiting
CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus[NCT00141453]	Phase 3	577 participants (Actual)	Interventional	2003-04-30	Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans[NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
Single-Dose Fed In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers[NCT00648219]	Phase 1	36 participants (Actual)	Interventional	2005-12-31	Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers[NCT00649623]	Phase 1	36 participants (Actual)	Interventional	2005-12-31	Completed
A Randomized, Open-label, Single-Dose, 2-Way Cross-over Study To Compare the Safety and Pharmacokinetic Characteristics of Combination of Amlodipine, Olmesartan and Rosuvastatin and DWJ1351 in Healthy Male Volunteers[NCT02665832]	Phase 1	58 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension[NCT00856271]	Phase 3	287 participants (Actual)	Interventional	2004-08-31	Completed
A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension[NCT00527514]	Phase 3	185 participants (Actual)	Interventional	2007-09-30	Completed
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study of the Efficacy, Safety and Tolerability of TAK-491 in Subjects With Mild to Moderate Uncomplicated Essential Hypertension[NCT00362115]	Phase 2	449 participants (Actual)	Interventional	2006-05-31	Completed
A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension[NCT00696436]	Phase 3	1,291 participants (Actual)	Interventional	2008-04-30	Completed
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV)[NCT00679484]	Phase 3	400 participants (Anticipated)	Interventional	2008-06-30	Terminated(stopped due to Lack of subject recruitment)
Effects of Mineralocorticoid and AT-1 Receptor Antagonism on the Aldosterone-Renin Ratio (ARR) In Primary Aldosteronism Patients (EMIRA Study): Rationale and Design[NCT04185857]		50 participants (Actual)	Observational	2018-01-01	Completed
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy[NCT00791258]	Phase 4	999 participants (Actual)	Interventional	2008-11-30	Completed
A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension[NCT02609490]	Phase 3	304 participants (Actual)	Interventional	2015-09-30	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment[NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension[NCT01033071]	Phase 3	1,071 participants (Actual)	Interventional	2010-01-31	Completed
AN OPEN LABEL, NON-INTERVENTIONAL STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF AMLODIPINE AND OLMESARTAN MEDOXOMIL (NORMETECTM) IN FILIPINO PATIENTS WITH HYPERTENSION: A POST MARKETING SURVEILLANCE STUDY[NCT01200407]		615 participants (Actual)	Observational	2010-06-09	Terminated(stopped due to The requirement for Post Marketing Surveillance was lifted by the Philippine FDA)
A Multi-center, Randomized, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWJ1451 in Patients With Hypertension and Dyslipidemia[NCT04161001]	Phase 3	237 participants (Anticipated)	Interventional	2019-11-20	Recruiting
A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension[NCT00649389]	Phase 3	2,500 participants (Actual)	Interventional	2008-05-31	Completed
Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination[NCT00923091]	Phase 3	2,689 participants (Actual)	Interventional	2009-06-30	Completed
Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome[NCT00891267]	Phase 3	60 participants (Anticipated)	Interventional	2008-10-31	Completed
Single-Dose Fed Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers[NCT01019590]	Phase 1	36 participants (Actual)	Interventional	2006-11-30	Completed
Single-Dose Fasting Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers[NCT01020214]	Phase 1	36 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects[NCT00949884]	Phase 4	941 participants (Actual)	Interventional	2009-08-31	Completed
Single Dose Crossover Comparative Bioavailability Study of Olmesartan Medoxomil/Hydrochlorothiazide 40 mg/25 mg Film-Coated Tablets in Healthy Adult Subjects / Fasting State[NCT04138888]	Phase 1	32 participants (Anticipated)	Interventional	2019-10-31	Recruiting
An Exploratory Study of CS-3150 to Evaluate the Relation Between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients With Essential Hypertension[NCT02848170]		40 participants (Actual)	Interventional	2016-08-31	Completed
Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone[NCT00902538]	Phase 3	2,204 participants (Actual)	Interventional	2009-04-30	Completed
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Amlodipine 10 mg Plus Valsartan 160 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free C[NCT00523744]	Phase 3	257 participants (Actual)	Interventional	2007-07-31	Completed
Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension[NCT00311155]	Phase 4	694 participants (Actual)	Interventional	2006-03-31	Completed
A Clinical Trial of Renin Profiling in Selection of Initial Antihypertensive Drug[NCT00834600]		185 participants (Actual)	Interventional	2005-12-31	Completed
Phase III Study of Irbersartan for the Early Treatment of Severe Sepsis Patients[NCT01992796]	Phase 3	300 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment[NCT00151827]	Phase 3	393 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension[NCT00872586]	Phase 3	304 participants (Actual)	Interventional	2006-08-31	Completed
Prospective, Multicentric, Open Clinic Essay to Evaluate the Use of OLMETEC® (Olmesartan Medoxomile) and OLMETEC PLUS® (Olmesartan Medoxomile Hydrochlorothiazide) in Stade I and II, According to JNC VII[NCT00811226]		450 participants (Anticipated)	Observational	2007-04-30	Completed
Comparison of the Effects of Different Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea[NCT01028534]		150 participants (Anticipated)	Interventional	2010-07-31	Completed
A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension[NCT00430638]	Phase 4	278 participants (Actual)	Interventional	2006-12-31	Completed
Evaluation of Vascular Function, Effects of Exercise Training and Angiotensin Receptor II Antagonist in Patients With Type II Diabetes and Hypertension by Using Near-infrared Spectroscopy, Rapid Laser Doppler Blood Flow Imaging and Circulating Biomarkers[NCT01053026]		15 participants (Actual)	Observational	2009-12-31	Completed
Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?[NCT04606563]	Phase 3	341 participants (Actual)	Interventional	2020-10-09	Terminated(stopped due to DSMC recommendation due to futility)
Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers[NCT01907373]	Phase 4	12 participants (Actual)	Interventional	2009-08-31	Completed
Open-label, Randomized, Single Center, Paralleled Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia[NCT04061824]	Phase 4	150 participants (Actual)	Interventional	2016-05-24	Completed
The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE)[NCT00607035]	Phase 4	220 participants (Actual)	Interventional	2006-05-31	Completed
The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects[NCT00185055]	Phase 4	20 participants	Interventional	2004-11-30	Completed
The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension[NCT00185094]	Phase 4	60 participants	Interventional	2004-02-29	Completed
A Randomized, Double-blind, Placebo-controlled Factorial Study Evaluating the Efficacy and Safety of Co-administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension[NCT00185133]	Phase 3	1,900 participants	Interventional	2005-05-31	Completed
An Open-label Study of Olmesartan Medoxomil (CS-866) in Normotensive Patients With Chronic Glomerulonephritis or Diabetic Nephropathy[NCT00914524]	Phase 2	49 participants (Actual)	Interventional	2005-01-31	Completed
A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension[NCT00185120]	Phase 4	152 participants	Interventional	2005-09-30	Completed
Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP)[NCT00185159]	Phase 3	4,449 participants (Actual)	Interventional	2004-10-31	Completed
Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone[NCT00220233]	Phase 3	632 participants	Interventional	2005-04-30	Completed
Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)[NCT00454662]	Phase 4	5,141 participants (Actual)	Interventional	2007-04-30	Completed
Multi-Omics to Predict the Blood Pressure Response to Antihypertensives[NCT05917275]	Phase 4	96 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
[NCT01831479]	Phase 1	36 participants (Actual)	Interventional	2011-08-31	Completed
Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue[NCT02996916]	Phase 4	100 participants (Anticipated)	Interventional	2015-12-31	Recruiting
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of FDC of Olmesaartan Medoxomil, Amlopdipine and Hydrochlorothiazide (40+10+25) mg Tab [Torrent,India] Vs Tribenzor(40+10+25) mg Tab [ Daichi Sankyo, Inc USA] in Health[NCT02962336]	Phase 1	34 participants (Actual)	Interventional	2011-05-31	Completed
The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk[NCT00134160]	Phase 4	1,000 participants (Anticipated)	Interventional	2005-08-31	Completed
A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Mode[NCT00139698]	Phase 3	410 participants	Interventional	2005-09-30	Completed
Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension[NCT00185172]	Phase 3	2,333 participants (Actual)	Interventional	2002-01-31	Completed
Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy[NCT00220220]	Phase 3	429 participants (Anticipated)	Interventional	2005-04-30	Completed
A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate[NCT01309828]	Phase 3	153 participants (Actual)	Interventional	2011-03-31	Completed
Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation Trial (ANTIPAF Trial)[NCT00098137]	Phase 3	422 participants (Actual)	Interventional	2005-01-31	Completed
A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar ®HCT in Patients With Stage II Systolic Hypertension[NCT00185068]	Phase 4	110 participants	Interventional	2004-03-31	Completed
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)[NCT00185185]	Phase 3	165 participants (Actual)	Interventional	2001-11-30	Completed
Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance: Prospective, Randomized, Open, Blinded Outcome Evaluation, and Feasibility Trial[NCT03024476]	Phase 2	67 participants (Actual)	Interventional	2016-09-01	Completed
Effect of Olmesartan or Amlodipine on Serum Angiotensin(1-7) Levels and Vascular Functions in Patients With Type 2 Diabetes and Hypertension[NCT05189015]	Phase 4	80 participants (Actual)	Interventional	2021-01-01	Completed
Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial)[NCT00417222]	Phase 3	1,145 participants (Actual)	Interventional	2006-11-30	Completed
Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study).[NCT00295542]	Phase 4	3,344 participants (Actual)	Interventional	2000-03-31	Completed
Randomized, Single-Blind, Multicenter, Phase III, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.[NCT05110898]	Phase 3	400 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia[NCT01764295]	Phase 3	150 participants (Anticipated)	Interventional	2012-09-30	Completed
Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty[NCT04743063]		40,000 participants (Anticipated)	Observational	2021-01-14	Active, not recruiting
Angiotensin II Blockade and Adipose Tissue Inflammation in Obesity[NCT01684748]	Phase 4	20 participants (Actual)	Interventional	2009-02-28	Completed
National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine B[NCT00890591]	Phase 4	144 participants (Actual)	Interventional	2006-08-31	Completed
"A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker Olmesartan Medoxomil Versus Losartan in Patients With Mild to Moderate Essential Hypertension"[NCT00857285]	Phase 3	130 participants (Actual)	Interventional	2002-05-31	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control[NCT02483936]	Phase 3	348 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial[NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
An Open-label Study of the Single-dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension[NCT00151814]	Phase 1	24 participants (Actual)	Interventional	2005-09-30	Completed
A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease[NCT04120753]	Phase 4	106 participants (Actual)	Interventional	2019-08-26	Completed
CVD Risk and Prevention in Early Glucose Intolerance[NCT00122447]		84 participants (Actual)	Interventional	2005-05-31	Completed
Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial[NCT01611077]	Phase 4	88 participants (Actual)	Interventional	2012-01-31	Completed
Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan 40 mg / Amlodipine 10 mg in Patients With Insufficiently Controlled Hypertension Under Monotherapy With Candesartan 32 mg - an Open Phase IIIb Trial[NCT01613209]	Phase 3	83 participants (Actual)	Interventional	2011-12-31	Completed
A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension[NCT01870739]	Phase 2	115 participants (Actual)	Interventional	2013-10-31	Completed
A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension[NCT01615198]	Phase 3	588 participants (Actual)	Interventional	2012-08-31	Completed
Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy[NCT00362960]	Phase 3	300 participants	Interventional	2003-05-31	Completed
[NCT02373462]	Phase 4	1 participants (Actual)	Interventional	2015-08-25	Terminated(stopped due to The data of the paper referenced in the preparation of the protocols in this task were manipulated and the paper was withdrawn.)
Single-center, Randomized, Open-label, Parallel-group Study to Characterize Renin-angiotensin-system (RAS) Peptide Profiles Before and After Treatment Initiation With Different Antihypertensive Drug-classes in Patients With Treatment-naive Arterial Hypert[NCT02449811]		107 participants (Actual)	Observational	2015-04-30	Completed
Lowering Blood Pressure in Primary Care in Vienna[NCT02377661]	Phase 4	229 participants (Actual)	Interventional	2015-03-31	Completed
Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension[NCT00151775]	Phase 2/Phase 3	362 participants (Actual)	Interventional	2005-05-31	Completed
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension[NCT01785472]	Phase 3	1,438 participants (Actual)	Interventional	2013-04-30	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control[NCT02493322]	Phase 3	261 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan[NCT01271374]	Phase 4	80 participants (Anticipated)	Interventional	2010-04-30	Active, not recruiting
A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension[NCT01692301]	Phase 2	454 participants (Actual)	Interventional	2012-12-31	Completed
A Two-arm, Open-label, Single-sequence, Multiple Oral Dosings, Cross-over Design Clinical Trial to Evaluate the Safety and Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers[NCT04856969]	Phase 1	38 participants (Actual)	Interventional	2021-03-30	Completed
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan[NCT01876368]	Phase 3	376 participants (Actual)	Interventional	2013-09-30	Completed
The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease by Smart Angioplasty Research Team: SMART-ROAD Trial[NCT02516826]	Phase 2	504 participants (Anticipated)	Interventional	2015-08-31	Not yet recruiting
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fasted Condition[NCT03318354]	Phase 1	34 participants (Actual)	Interventional	2010-05-31	Completed
Efficacy and Safety of s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension:a Randomized,Double-blind,Placebo-controlled,Multicenter Phase II Clinical Trial[NCT05033535]	Phase 2	10 participants (Anticipated)	Interventional	2020-07-01	Recruiting
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension[NCT01599104]	Phase 3	1,161 participants (Actual)	Interventional	2012-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 2 Hours of the Last (Week 12) 24-hour Dosing Period.

Participants had a 24-hour ambulatory blood pressure session at baseline and after 12 weeks of treatment. This outcome measure pooled all participants regardless of their titration history during the study. (NCT00403481)
Timeframe: baseline and 12 weeks

Intervention	mm Hg (Mean)
Overall Study Population	-18.6

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-33.0
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-34.1
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-26.9

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-37.6
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-38.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-31.5

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-14.4	-15.4
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.8	-16.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.8	-12.1

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=360; n=347; n=352)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.6	-16.1
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.2	-16.5
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.4	-12.8

Intervention	percentage of participants (Number)
	Week 2 (n=343; n=334; n=345)	Week 4 (n=360; n=347; n=352)	Week 6 (n=362; n=350; n=353)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	51.3	58.1	68.8	69.4
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	48.5	61.4	65.4	68.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	35.9	44.6	55.5	54.7

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.2
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-5.3
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.1
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-2.0

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.0
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-5.5
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.0
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-1.8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.9
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-4.5
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.2
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-2.3

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-8.74
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-7.72
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-6.66
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-4.47

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-11.16
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-9.13
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-8.10
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-5.66

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-13.16
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-10.90
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-9.65
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-6.60

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-16.17
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-13.52
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-11.46
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-8.85

Intervention	Percent of participants (Number)
Olmesartan Tablets and a Calcium Channel Blocker Tablet	1.9
Olmesartan Medoxomil Tablets and a Diuretic	44.2

Intervention	Percent of participants (Number)
Olmesartan Tablets and a Calcium Channel Blocker Tablet	34.0
Olmesartan Medoxomil Tablets and a Diuretic	59.2

Intervention	mm Hg (Mean)
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-11.16
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-10.45

Intervention	mm Hg (Mean)
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-9.32
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-8.83

Intervention	mm Hg (Mean)
	Change from Week 8 to Wk 16 in mean 24-hr ABPM dBP	Change from Week 8 to wk16 in daytime ABPM dBP	Change from Week 8 to wk16 in nighttime ABPM dBP	Change from Week 8 to wk16 in mean 24-hr ABPM sBP	Change from Week 8 to wk16 in daytime ABPM sBP	Change from Week 8 to wk16 in nighttime ABPM sBP
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-7.6	-7.7	-7.0	-12.0	-12.3	-10.7
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-9.2	-9.3	-8.6	-14.7	-15.0	-13.4

Intervention	mm Hg (Mean)
	Change from baseline (Week 8) to Week 16 in sBP	Change from baseline (Week 8) to Week 12 in sBP
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-17.09	-13.80
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-17.41	-14.07

Intervention	participants (Number)
	BP<140/90 mm Hg	SBP<140 mm Hg	DBP<90 mm Hg
Overall Study	133	133	149

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-7.71
Azilsartan Medoxomil 40 mg QD	-8.43
Azilsartan Medoxomil 80 mg QD	-8.87
Olmesartan 40 mg QD	-7.82
Placebo QD	-0.59

olmesartan

Description

Cross-References

Synonyms (106)

Research Excerpts

Overview

Effects

Actions

Treatment

Roles (2)

Drug Classes (1)

Pathways (4)

Protein Targets (8)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (34)

Molecular Functions (30)

Ceullar Components (12)

Bioassays (93)

Research

Studies (803)

Study Types

Clinical Trials (133)

Trial Overview

Trial Outcomes

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 2 Hours of the Last (Week 12) 24-hour Dosing Period.

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 4 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 6 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Change From Baseline to Week 12 in Mean 24-hour Ambulatory BP (Diastolic)

Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM.

Change in Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12 During the Last 2 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Change From Baseline to Week 12 in Mean Daytime and Nighttime Ambulatory Blood Pressure Measurement (Systolic).

Change in Ambulatory BP (Diastolic) From Baseline to Week 12 During the Last (Week 12 ) 4 and 6 Hours of the Last 24-hour Dosing Period.

Change in Daytime and Nighttime Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12

Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.

Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.

Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure

Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD

Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change in Mean Night-time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.

Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16

Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.

Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.

Number of Patients Achieving Target Blood Pressure at Week 16

Percent of Patients With Drug-related Adverse Events (Laboratory Changes in Clinical Laboratory Values)

Percentage of Patients With Drug-related Adverse Events (Subjective Symptoms/Objective Findings)

The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85

Change in Mean Trough Sitting Diastolic Blood Pressure

Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12

Number of Participants Achieving Blood Pressure Goal.

Change in Daytime, Nighttime and 24-hour Blood Pressure Evaluated by Ambulatory Blood Pressure Monitoring 8 Weeks After Baseline.

Change in Sitting Systolic Blood Pressure 4 Weeks and 8 Weeks After Baseline.

Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure After 12 Weeks of Active Treatment.

Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment

Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10 Pm-6am) Ambulatory Blood Pressure Monitored Diastolic Blood Pressure After 12 Weeks of Active Treatment

Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10pm-6am)Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment

Number of Subjects Who Achieved Mean 24-hour Ambluatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment

Number of Subjects Who Achieved Mean Daytime (8am - 4pm) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.

Number of Subjects Who Achieved Mean Nighttime (10pm - 6am) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.

Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure

Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure

Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-12.57
Azilsartan Medoxomil 40 mg QD	-13.75
Azilsartan Medoxomil 80 mg QD	-14.96
Olmesartan 40 mg QD	-12.73
Placebo QD	-1.54

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-6.82
Azilsartan Medoxomil 40 mg QD	-6.86
Azilsartan Medoxomil 80 mg QD	-8.42
Olmesartan 40 mg QD	-6.91
Placebo QD	0.21

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-14.28
Azilsartan Medoxomil 40 mg QD	-14.47
Azilsartan Medoxomil 80 mg QD	-17.58
Olmesartan 40 mg QD	-14.87
Placebo QD	-2.06

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-12.72
Azilsartan Medoxomil 40 mg QD	-14.05
Azilsartan Medoxomil 80 mg QD	-15.18
Olmesartan 40 mg QD	-13.07
Placebo QD	-1.36

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-7.47
Azilsartan Medoxomil 40 mg QD	-8.38
Azilsartan Medoxomil 80 mg QD	-8.61
Olmesartan 40 mg QD	-7.74
Placebo QD	-0.69

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-12.15
Azilsartan Medoxomil 40 mg QD	-13.48
Azilsartan Medoxomil 80 mg QD	-14.62
Olmesartan 40 mg QD	-12.56
Placebo QD	-1.40

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-6.98
Azilsartan Medoxomil 40 mg QD	-7.90
Azilsartan Medoxomil 80 mg QD	-7.79
Olmesartan 40 mg QD	-7.62
Placebo QD	-0.96

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-11.10
Azilsartan Medoxomil 40 mg QD	-12.39
Azilsartan Medoxomil 80 mg QD	-13.35
Olmesartan 40 mg QD	-12.13
Placebo QD	-0.97

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg QD	-7.96
Azilsartan Medoxomil 40 mg QD	-7.93
Azilsartan Medoxomil 80 mg QD	-8.68
Olmesartan 40 mg QD	-7.56
Placebo QD	-1.12

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 20 mg QD	67.5
Azilsartan Medoxomil 40 mg QD	71.0
Azilsartan Medoxomil 80 mg QD	73.5
Olmesartan 40 mg QD	73.9
Placebo QD	47.9